Study of Blood Clotting Disorders in Patients with Ischemic and Hemorrhagic Stroke or Aneurysmal Subarachnoid Hemorrhage Mapping Coagulation and Inflammation Markers to Predict Outcomes After Stroke

What this Trial Is About

Researchers are studying coagulation disorders in patients with acute ischaemic stroke, haemorrhagic stroke, and aneurysmal subarachnoid haemorrhage. The main goal is to map both procoagulant and anticoagulant pathways, as well as inflammation and neuronal ischemia markers, to identify biochemical indicators that might predict survival and functional outcomes at three months. The study also explores underlying thrombophilia, the effects of pre-stroke medications, and platelet function related to delayed cerebral ischemia after aneurysmal subarachnoid haemorrhage. Participants receive care in emergency or intensive care settings where clinical and blood data are collected. Blood samples are taken at five time points during the first week after admission for detailed coagulation and cell-free DNA methylation testing, alongside standard clinical blood tests. Subgroups include patients with ischemic stroke, haemorrhagic stroke, and aneurysmal subarachnoid haemorrhage, each monitored closely to investigate specific pathophysiological mechanisms. During the study, patients have baseline clinical data and blood tests recorded with follow-up blood sampling within the first week. Researchers assess outcomes like functional status using scales at three months, mortality, stroke recurrence, and other clinical events such as intensive care needs and complications. The study provides detailed monitoring of coagulation and inflammatory markers to better understand disease progression and potential future treatments.

COAgulation Disorders in Ischaemic and Haemorrhagic Stroke